Advanced hybrid closed loop therapy

About advanced hybrid closed loop therapy

Hybrid closed loop systems use control algorithms to automate basal insulin delivery, based on glucose sensor values. Studies have demonstrated that hybrid closed loop systems improve HbA1c and time in range in people with T1D, while reducing hypoglycaemia and lowering HbA1c, compared to gold-standard insulin therapy.¹

Advanced hybrid closed loop therapy consists of three components:

A ‘smart’ insulin pump
A continuous glucose monitoring (CGM) system
Therapy management software

Together, these features act on behalf of the user, mimicking some functions of a healthy pancreas, to deliver advanced glucose control.

Advanced hybrid closed loop systems, such as the MiniMed™ 780G, with SmartGuard® technology, automatically adjusts basal insulin delivery every five minutes, based on CGM readings. This cutting-edge technology helps users spend more time in range (3.9 mmol/L – 10 mmol/L) and reduces the burden of managing diabetes compared with MDI.

CGM and time in range

CGM improves time in range and glycaemic control. Several randomised controlled trials ^2-6 showed that CGM can lead to ⁶:

Reduced glycaemic variability – an average of 72% time in range
Up to 27% less time in high range
A 98% improvement in HbA1c when compared to MDI
Greater number of patients reaching the HbA1c target recommended by the American Diabetes Association

MiniMed™ 780G+G4 system

The only available system that automatically adjusts and corrects every 5 minutes, so you don’t have to.

SmartGuard® technology

Research has shown that:

5-minute auto corrections
Auto-corrections can be delivered up to 12 times every hour, day or night
Includes meal detection module
If a meal is detected, intelligent auto correction boluses are able to adjust for inaccurate carb count or occasional missed meal dose
Treat to target
Select from three targets: 5.5, 6.1 or 6.7 mmol/L
Auto-basal
Automation not based on pre-set basal rates
Connect to app
Automatic upload to CareLink Connect App every 24 hours

How does it work?

CGM improves time in range and glycaemic control. Several randomised controlled trials^2-6 showed that CGM can lead to: ⁶

SmartGuard® Auto Mode is designed to determine an individual’s insulin needs and to take action to reduce high and low glucose levels, to spend more time in range
Guardian™ Sensor 4 sits under the skin in the interstitial fluid, where cells get oxygen and nutrients, including glucose
Guardian™ Sensor 4 sits under the skin in the interstitial fluid, where cells get oxygen and nutrients, including glucose

Learn more

References

1. Petrovski G et al. BMC Endocrine Disord 2022; https://doi.org/10.1186/s12902-022-00996-7 2. Bergenstal RM et al. JAMA 2016; 316:1408. 3. Juvenille Diabetes Research Foundation Continuous Glucose Monitoring Study Group. N Engl J Med 2008; 359:1464-67. 4. Raccah D et al. Diabetes Care 2009; 32:2245-50. 5. Kaufman FR et al. N Engl J Med 2010; 363:311-20. 6. Data on file.

Search form

You are here